Medical Treatment of Ascites in Cirrhosis

Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment: Second Edition

Volumn , Issue , 2007, Pages 227-240

  Angeli, Paolo ^a   Gatta, Angelo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Ascites; Blood culture; Cirrhosis; Hypertension; Sympathetic nervous system

Indexed keywords

EID: 84889352909     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987476.ch18     Document Type: Chapter

References (138)

1. Reynolds TB. Ascites. Clin Liver Dis 2000; 4:151-68.
2. Rimola A, Garcia-Tsao G, Navasa M et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000; 32:142-53.
3. Runyon BA. Cardiac ascites: a characterization. J Clin Gastroenterol 1988; 10:410-12.
4. Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchinson JG. The serum ascites albumin gradient is superior to the exudates-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992; 117:215-20.
5. Arroyo V, Ginès P, Planas R, Panes J, Rodés J. Management of patients with cirrhosis and ascites. Semin Liv Dis 1986; 6:353-69.
6. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium retention and water retention in cirrhosis. Hepatology 1988; 8:1151-7.
7. Conn HO, Fessell JM. Spontaneous bacterial peritonitis in cirrhosis. Variations on a theme. Medicine 1971; 50:161-7.
8. Conn HO. Rational management of ascites. In: Popper H, Shaffer F, eds. Progress in Liver Disease, Vol. 4. New York. Grune & Stratton, 1972; 269-80.
9. Arroyo V, Rodés J. A rational approach to the treatment of ascites. Postgrad Med J 1975; 51:558-62.
10. Gentilini P, La Villa G, Laffi G et al. Sodium retention in cirrhosis: aspects of pathophysiology and treatment. Front Gastrointest Res 1986; 9:203-18.
11. Gatta A., Angeli P, Caregaro L, Menon F, Sacerdoti D, Merkel C. A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients with ascites. Hepatology 1991; 14:231-6.
12. Bernardi M, Laffi G, Salvagnini M et al. Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content. Liver 1993; 13:156-62.
13. Bernardi M, Santini C, Trevisani F, Baraldini M, Ligabue A, Gasparrini G. Renal function impairment induced by change in posture in patients with cirrhosis and ascites. Gut 1985; 26:629-35.
14. Ring-Larsen H, Henriksen JH, Wilken C, Clausen J, Pals H, Chistensen NJ. Diuretic treatment in decompensated cirrhosis and congestive heart failure: effects of posture. Brit Med J 1986; 292:1351-3.
15. Reynolds TB, Lieberman FL, Goodman AR. Advantages of treatment of ascites without sodium restriction and without complete removal of excess fluid. Gut 1978; 19:549-53.
16. Strauss E, De Sa MF, Lacet CM, Cartapattida da Silva E, Dos Santos RW. Pradonizaçao de conducta terapeutica das ascites do heapatopata cronico. Estudio prostectivo de 100 casos. GED 1985; 4:79-86.
17. Descos L, Gauthier A, Levy VG et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepatogastroenterology 1983; 30:15-20.
18. Gauthier A, Levy VG, Quinton A. Salt or not salt in the treatment of cirrhotic ascites: a randomized study. Gut 1986: 27:705-9.
19. Moore KP, Wong F, Ginès P et al. The management of ascites in cirrhosis: report of the Consensus Conference of the International Ascites Club. Hepatology 2003; 38:258-66.
20. Arroyo CV, Ginès P, Jiménez W, Rodés J. Ascites, renal failure, and electrolyte disorders in cirrhosis. Pathogenesis, diagnosis and treatment. In: McIntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodés J. eds. Oxford Textbook of Clinical Hepatology, Vol. 1. Oxford: Oxford University Press, 1991; 429-70.
21. Sherlock S. Dietary sodium restriction during diuresis of ascites. Hepatology 1987; 7:789-90.
22. Caregaro L, Alberino F, Amodio P et al. Malnutrition in alcoholic and virus-related cirrhosis. Am J Clin Nutr 1996; 63:602-9.
23. Runyon BA. Care of patients with ascites. N Engl J Med 1994; 330:337-42.
24. Ginés P, Arroyo V, Rodés J. Pharmacotherapy of ascites associated with cirrhosis. Drugs 1992; 43:316-32.
25. Knauf H, Wenk E, Sholmerich J et al. Prediction of diuretic mobilization of cirrhotic ascites by treatment fractional sodium excretion. Klin Wochenschr 1990; 68:545-51.
26. Grenger R. New insights into the molecular mechanisms of the action of diuretics. Nephrol Dial Transplant 1999; 14:536-40.
27. Odlind B, Beermann B. Renal tubular secretion and effects of furosemide. Clin Pharmacol Ther 1980; 27:784-90.
28. Suki WN, Stinebaugh BJ, Frommer JP, Eknoyan G. Physiology of diuretic action. In: Seldin DW, Giebish G, eds. The Kidney, Physiology and Pathophysiology. New York: Raven Press, 1985; 2127-62.
29. Shankar SS, Brater DG. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol 2003; 284:F11-F21.
30. Haas M. Properties and diversity of (Na-K-Cl) cotransporters. Annu Rev Physiol 1989; 51:443-57.
31. Haas M, McManus TJ. Bumetanide inhibits (Na+, K+, Cl) co-transport at a chloride site. Am J Physiol 1983; 245: C235-C240.
32. Friedel AF, Buckley MMT. Torasemide. A review of its pharmacological properties and therapeutic potential. Drugs 1991; 41:81-103.
33. Nies AS, Gal J, Fadul S, Gerber JG. Indomethacin-furosemide interaction: the importance of renal blood flow. J Pharmacol Ther 1983; 226:27-32.
34. Rane A, Villeneuve JP, Stone WJ et al. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin Pharmacol Ther 1978; 24:199-207.
35. Brater DC. Resistance to loop diuretics. Why it happens and what to do about it. Drugs 1985; 30:437-43.
36. Rose BD. Diuretics. Kidney Int 1991; 39:336-52.
37. Brater DC. Clinical pharmacokinetics. In: Eynoyan G, Martinez-Maldonado M, eds. The Physiological Basis of Diuretic Therapy in Clinical Medicine. Orlando: Grune & Stratton, Inc., 1986; 27-55.
38. Kinsella JL, Aronson PS. Amiloride inhibition of the Na+-H+ exchanger in renal microvillus membrane vesicles. Am J Physiol 1981; 241:F374-F379.
39. Benos DJ. Amiloride: a molecular probe of sodium transport in tissues and cells. Am J Physiol 1982; 242:C131-C145.
40. Frehaland E, Hoshiko T, Machlup S. Cooperative blocking of apical sodium channels in epithelia. Biochim Biopys Acta 1983; 732:636-46.
41. Smith AJ, Smith RN. Kinetics and bioavailability of two formulations of amiloride in man. Br J Pharmacol 1973; 48:646-9.
42. Macfie HL, Colvin CL, Anderson PO. New drug evaluations: amiloride. Drug Intell Clin Pharm 1981; 15:94-8.
43. Mutschler E, Gilfrich HJ, Knauf H, Mohrke W, Volger KD. Pharmacokinetics of triamterene in healthy subjects and patients with liver and kidney function disorders. Klin Wochenschr 1983; 15:883-91.
44. Knauf H, Mohrke W, Mutshler E. Delayed elimination of triamterene and its metabolite in chronic renal failure. Eur J Clin Pharmacol 1983; 24:453-6.
45. Sansom SC, O'Neil RG. Effects of mineralocorticoids on transport properties of cortical collecting duct basolateral membrane. Am J Physiol 1986; 251:F743-F757.
46. Bartlet-Bas C, Kjadouri C, Marsy S, Doucet A. Sodiumindependent in vitro induction of Na+, K,-ATPase by aldosterone in renal target cells: permissive effect of triiodothyronine. Proc Natl Acad Sci USA 1988; 85:1707-11.
47. Bartlet-Bas C, Kjadouri C, Marsy S, Doucet A. Enhanced intracellular sodium concentration in kidney cells recruits a latent pool of Na-K-ATPase whose size is modulated by corticosteroids. Proc Natl Acad Sci USA 1990; 265:7799-803.
48. Corvol P, Claire M, Oblin ME, Geerin K, Rossier B. Mechanism of the antimineralcorticoid effects of spironolactones. Kidney Int 1981; 20:1-6.
49. Blaine EH. Basic principles of renal physiology and pharmacology. In: Cragoe EJ Jr, ed. Diuretics: Chemistry, Pharmacology, and Medicine. New York: John Wiley, 1983; 17-48.
50. Karim A. Spironolactone metabolism in man revisited. In: Brunner HR, ed. Contemporary Trends in Diuretic Therapy. Amsterdam: Excerpta Medica, 1986; 22-37.
51. Mutshler E. Knauf H. Pharmacokinetics of potassium retaining diuretics. In: Pushett JB, Greenberg A, eds. Diuretics: Chemistry, Pharmacology, and Clinical Applications. New York: Elsevier, 1984; 290-8.
52. Sungaila I, Bartle WR, Walker SE et al. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology 1992; 102:1680-5.
53. Epstein M. Renal sodium handling in liver disease. In: Epstein M, ed. The Kidney in Liver Disease. Philadelphia: Hanley & Belfus, 1996; 1-31.
54. Chiandussi L, Bartoli E, Arras S. Reabsorption of sodium in the proximal renal tubule in cirrhosis of the liver. Gut 1978; 19:497-503.
55. Wilkinson SP, Jowett TP, Slater JDH, Arroyo V, Moodie H, Willims R. Renal sodium retention in cirrhosis: relation to aldosterone and nephron site. Clin Sci 1972; 56:169-77.
56. Chaimovitz C, Szylman P, Alroy G, Better OS. Mechanism of increased renal tubular sodium reabsorption in cirrhosis. Am J Med 1972; 52:198-202.
57. Rochamn J, Chaimovitz C, Szylman P. Better OS. Tubular handling of sodium and phosphate in cirrhosis with salt retention. Nephron 1978; 20:95-100.
58. Epstein M, Ramachandran M, De Nunzio AG. Interrelationship of renal sodium and phosphate handling in cirrhosis. Mineral Electrolyte Metab 1982; 7:305-15.
59. Thomsen K, Schou M, Steiness I, Hansen HE. Lithium as an indicator of proximal sodium reabsorption. Plugers Arch 1969; 308:180-4.
60. Angeli P, De Bei E, Dalla Pria M et al. Effects of amiloride on renal lithium handling in nonazotemic ascitic cirrhotic patients with avid sodium retention. Hepatology 1992; 15:651-4.
61. Angeli P, Gatta A, Caregaro L et al. Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance. Eur J Clin Invest 1990; 20:111-17.
62. Diez J. Simon A, Anton F, Indart FJ, Prieto J. Tubular sodium handling in cirrhotic patients with ascites as analyzed by the renal lithium clearance method. Eur J Clin Invest 1990; 20:266-71.
63. Jonassen TEN, Sorensen AM, Petersen JS, Andreasen F, Christensen S. Increased natriuretic efficiency of furosemide in rats with carbon tetrachloride-induced cirrhosis. Hepatology 2000; 31:1224-30.
64. Pérez-Ayuso RM, Arroyo V, Planas R et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Gastroenterology 1984; 84:961-8.
65. Sawhney VK, Gregory PB, Swezey SE, Blaschke TF. Furosemide disposition in cirrhotic patients. Gastroenterology 1981; 81:1012-16.
66. Gonzalez G, Arancibia A, Rivas MJ, Caro P, Antezana C. Pharmacokinetics of furosemide in patients with hepatic cirrhosis. Eur J Clin Pharmacol 1982; 22:315-20.
67. Pinzani M, Daskalopuoulus G, Laffi G, Gentilini G, Zipster RD. Altered furosemide pharmacokinetics in chronic alcoholic liver disease with ascites contributes to diuretic resistance. Gastroenterology 1987; 92:294-8.
68. Allgulander C, Beerman B, Sjogren A. Furosemide pharmacokinetics in patients with liver disease. Clin Pharmacokinet 1980; 5:570-5.
69. Keller E, Hoppe-Seyler G, Mumm R, Schollmeyer P. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics J Clin Pharmacol 1981; 20:27-33.
70. Verbeeck RK, Patwardhan RV, Villeneuve JP, Wilkinson GR, Branch RA. Furosemide disposition in cirrhosis. Clin Pharmacol Ther 1982; 31:719-35.
71. Traeger A, Hantze R, Penzlin M et al. Pharmacokinetics and pharmacodynamic effects of furosemide in patients with liver cirrhosis. Int J Clin Pharmacol 1985; 23:129-33.
72. Villeneuve JP, Verbeek RK, Wilkinson GR, Branch RA. Furosemide kinetics and dynamics in patients with cirrhosis. Clin Pharmacol Ther 1986; 40:14-20.
73. Angeli P, Dalla Pria M, De Bei E et al. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology 1994; 19:72-9.
74. Boyer TD, Warnock DG. Use of diuretics in the treatment of cirrhotic ascites. Gastroenterology 1983; 84:1051-5.
75. Bernardi M, Servadei D, Trevisani F, Rusticali AG, Gasbarrini G. Importance of plasma aldosterone concentration on natriuretic effect of spironolactone in patients with liver cirrhosis and ascites. Digestion 1985; 31:189-93.
76. Lim YS, Han JS, Kim KA, Yoon JH, Lee HS. Monitoring of transtubular potassium gradient in the diuretic management of patients with cirrhosis and ascites. Liver 2002; 22:426-32.
77. Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, Sanchez de la Cuesta F, and the Spanish Collaborative Study Group on therapeutic management in liver disease. Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. Eur J Clin Pharmacol 2002; 58:435-40.
78. Santos J, Planas R, Pardo A et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol 2003; 39:187-92.
79. Shear LS, Ching S, Gabuzda GJ. Compartmentalization of ascites and edema in patients with cirrhosis. N Engl J Med 1970; 282:1391-5.
80. Fernandez-Esparrach G, Guevara M, Sort P et al. Diuretic requirements after therapeutic paracentesis in nonazotemic patients with cirrhosis. A randomized doubleblind trial of spironolactone versus placebo. J Hepatol 1997; 26:614-20.
81. Runyon BA. Refractory ascites. Semin Liv Dis 1993; 13:343-51.
82. Angeli P, Caregaro L, Menon F. Variability of atrial natriuretic peptide plasma levels in ascitic cirrhotics; pathophysiological and clinical implications. Hepatology 1992; 16:1389-94.
83. Wong F, Sheldon T, Lagault L et al. Refractory ascites in cirrhosis: roles of volume expansion and plasma atrial natriuretic factor level elevation. Hepatology 1993; 18:519-28.
84. Caregaro L, Menon F, Angeli P et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 1994; 154:201-5.
85. Arroyo V, Ginès P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome. Hepatology 1996; 23:164-76.
86. Sphar L, Villeneuve JP, Tran HK, Pmier-Layrargues GP. Furosemide-induced natriuresis as a test to identify cirrhotic patients with refractory ascites. Hepatology 2001; 33:28-31.
87. Arroyo V, Epstein M, Gallus G, Gentilini P, Ring-Larsen H, Salerno F. Refractory ascites in cirrhosis: mechanism and treatment. Gastroenterol Int 1989; 4:195-207.
88. Mirouze D, Zipster RD, Reynolds TB. Effects of inhibitors of prostaglandin synthesis on induced diuresis in cirrhosis. Hepatology 1983; 3:50-5.
89. Planas R, Arroyo V, Rimola A, Perez-Ayuso RM, Rodés J. Acetylsalicylic acid suppresses the renal haemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites. Gastroenterology 1983; 84:247-52.
90. Descalopoulos G, Laffi G, Morgan T et al. Immediate effects of furosemide on renal haemodynamics in chronic liver disease with ascites. Gastroenterology 1987; 92:1959-63.
91. Hellison DH. Diuretic drugs and treatment of edema: from clinic to bench and back again. Am J Kidney Dis 1994; 23:623-43.
92. Gerbes AL, Bertheau-Reitha U, Falkner C, Jungst D, Paumgartner G. Advantages of a new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. A randomized, double blind cross-over trial. J Hepatol 1993; 17:353-8.
93. Laffi G, Marra F, Buzzelli G et al. Comparison of the effects of torasemide and furosemide in nonazotemic cirrhotic patients with ascites: a randomized double-blind study. Hepatology 1991; 13:1101-5.
94. Epstein M, Lepp BA, Offman DS, Levinson R. Potentiation of furosemide by metolazone in refractory edema. Curr Ther Res 1977; 21:656-67.
95. Knauf H, Mutschler E. Low-dose segmental blockade of the nephron rather than high-dose diuretic monotherapy. Eur J Clin Pharmacol 1993; 44 (Suppl. 1):S63-S68.
96. Morali GA, Tobe SW, Skorecki KL, Blendis LM. Refractory ascites: modulation of atrial natriuretic factor unresponsiveness by mannitol. Hepatology 1992; 16:42-8.
97. Pamuk ON, Sonsuz A. The effect of mannitol infusion on the response to diuretic therapy in cirrhotic patients with ascites. J Clin Gastroenterol 2002; 35:403-5.
98. Gentilini P, Casini Raggi V, Di Fiore G et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 1999; 30:639-45.
99. Angeli P, Albino G, Carraro P et al. Cirrhosis and muscle cramps: evidence of a causal relationship. Hepatology 1996; 23:264-73.
100. Sherlock S, Senewiratne B, Scott A, Walker JG. Complications of diuretic therapy in hepatic cirrhosis. Lancet 1966; 1:1049-53.
101. Strauss E, De Sa MF, Lacet CM, Cartapattida da Silva E, Regina dos Santos W. Standardization of a therapeutic approach for ascites due to chronic liver disease: a prospective study of 100 cases. GED 1985; 4:79-86.
102. Pockros PJ, Reynolds TB. Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema. Gastroenterology 1986; 90:1827-33.
103. Gregory P, Broekelschen PH, Hill MD et al. Complications of diuresis in the alcoholic patient with ascites: a controlled trial. Gastroenterology 1977; 73:534-8.
104. Ferenci P. Hepatic encephalopathy. In: McIntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodés J, eds. Oxford Textbook of Clinical Hepatology, Vol. 1. Oxford: Oxford University Press, 1991; 473-83.
105. Baertl JM, Sancelta SM, Gabuzda GJ. Relation of potassium depletion to renal ammonium metabolism in patients with cirrhosis. J Clin Invest 1963; 42:696-707.
106. Jaeger P, Karlmark B, Giebish G. Ammonium transport in rat cortical tubule: relationship to potassium metabolism. Am J Physiol 1983; 245:F593-F600.
107. Haussinger D. Organization of hepatic nitrogen metabolism and its relation to acid-base homeostasis. Klin Wochenschr 1990; 68:1096-101.
108. Lieberman FL, Reynolds TB. The use of ethacrinic acid in patients with cirrhosis and ascites. Gastroenterology 1965; 49:531-8.
109. Campra JL, Reynolds TB. Effectiveness of high-dose spironolactone therapy in patients with chronic liver disease and relatively refractory ascites. Dig Dis Sci 1978; 23:1025-30.
110. Alexander EA, Levinsky NG. An extrarenal mechanism of potassium adaptation. J Clin Invest 1968; 47:740-8.
111. Gross P, Ketteler M, Hausamann C et al. Role of diuretics, hormonal derangements, and clinical setting of hyponatremia in medical patients. Klin Wochenschr 1988; 66:662-9.
112. Porcel A, Diaz F, Rendon P, Macias M, Martin-Herera L, Giron-Gonzales JA. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern Med 2002; 162: 323-8.
113. Borroni G, Maggi A, Sangiovanni A, Cazzaniga M, Salerno F. Clinical relevance of hyponatremia for the hospital outcome of cirrhotic patients. Dig Liver Dis 2000; 32:605-11.
114. Gabow PA, Moore S, Schrier RW. Spironolactone induced hyperchloremic acidosis in cirrhosis. Ann Intern Med 1979; 90:338-40.
115. Johnson PJ. The effect of liver disease on the endocrine system. In: McIntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodés J, eds. Oxford Textbook of Clinical Hepatology, Vol. 2. Oxford: Oxford University Press, 1991; 1214-24.
116. Loriaux DL, Menard R, Taylor A, Pita JC, Santen R. Spironolactone and endocrine dysfunction. Ann Intern Med 1976; 85:630-6.
117. Corvol P, Michael P, Menard J, Freifild M, Mahoudeau J. Antiandrogenic effect of spironolactone: mechanism of action. Endocrinology 1975; 97:52-8.
118. Bellati G, Ideo G. Gynaecomastia after spironolactone and potassium canrenoate. Lancet 1985; 1:626.
119. Andriulli A, Arrigoni A, Gindro T, Karbowiak I, Buzzetti G, Armanini D. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy. Digestion 1989; 44:155-62.
120. Dupont A. Disappearance of spironolactone-induced gynecomastia during treatment with potassium canrenoate. Lancet 1985; 2:731.
121. Francavilla A, Di Leo A, Eagon PK et al. Effect of spironolactone and potassium canrenoate on cytosolic and nuclear androgen and estrogen receptors of rat liver. Gastroenterology 1987; 93:681-6.
122. Konikoff F, Theodor E. Painful muscle cramps: a symptom of liver cirrhosis? J Clin Gastroenterol 1986; 8:669-72.
123. Lee FY, Lee SD, Tsai YT et al. A randomized controlled trial of quinidine in the treatment of cirrhotic patients with muscle cramps. J Hepatol 1991; 12:236-40.
124. Kagelmans M. Preliminary observation: oral zinc sulfate replacement is effective in treating muscle cramps in cirrhotic patients. J Am Col Nutr 2000; 19:13-15.
125. Rodés J. The evolution of knowledge on the pathophysiology of portal hypertension. In: De Franchis R, ed. Portal Hypertension II. Cambridge: Blackwell Science, 1996; 18-29.
126. Genecin P, Polio J, Groszmann RJ. Na restriction blunts expansion of plasma volume and ameliorates hyperdynamic circulation in portal hypertension. Am J Physiol 1990; 259:G498-G503.
127. Oberti F, Rifflet H, Maiga MY et al. Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation. J Hepatol 1997; 26:167-73.
128. Okumura H, Aramaki T, Katsuta Y et al. Reduction in hepatic pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. Am J Gastroenterol 1991; 86:46-52.
129. Garcia-Pagan JC, Salmeron JM, Feu F et al. Effects of low sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology 1994; 19:2095-9.
130. Nevens F, Lijnen P, VanBilloen H, Fevery J. The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. Hepatology 1996; 23:1047-52.
131. Garcia-Pagan JC, Salmeron JM, Feu F et al. Effects of low sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology 1994; 19:2095-9.
132. Sogni P, Soupison T, Moreau R et al. Hemodynamic effects of acute administration of furosemide in patients with cirrhosis receiving β-adrenergic antagonists. J Hepatol 1994; 20:548-52.
133. De Castele M, Van Roey G, Nevens F, Fevery J. Effects of varying doses of spironolactone without and with nitrates on portal vein pressure and kidney function in partial portal vein ligated rats. Hepatology 1996; 24:1492-6.
134. Abecasis R, Kravetz D, Fassio E et al. Nadolol plus spironolactone in the prophylaxis of the first variceal bleed in nonascitic cirrhotic patients: a preliminary study. Hepatology 2003; 37:359-65.
135. Koda M, Murawaki Y, Kawasaki H, Ikawa S. Effects of canrenoate potassium, an aldosterone antagonist on portal hemodynamics in patients with compensated liver cirrhosis. Hepato-Gastroenterology 1996; 43:887-92.
136. Cargnelli G, Trevisi L, Debetto P, Luciani S, Bova S. Effects of canrenone on aorta and right ventricle of the rat. J Cardiovasc Pharmacol 2001; 37:540-7.
137. Ngamukos C, Grekin RJ. Nontraditional aspects of aldosterone physiology. Am J Physiol Endocrinol Metab 2001; 281:E1122-E1127.
138. Caligiuri A, De Franco RMS, Romanelli RG et al. Antifibrogenic effects of canrenone, an antialdosteronic drug on human hepatic stellate cells. Gastroenterology 2003; 124:504-20.